GLAUKOS CORP

Navratil Tomas’s latest insider sale at Glaukos Corp shows disciplined 10b‑5‑1 trading, hinting at personal cash flow rather than a shift in confidence. Explore how this move may affect investor sentiment and Glaukos’s growth outlook.

Glaukos insider sell: Chief Development Officer Navratil Tomas executes a structured 10b5‑1 plan, shedding 103 shares at $163.20 while holding a core stake.

Glaukos insider buying signals confidence in its glaucoma therapy growth – investors should weigh the bullish momentum against the company’s current earnings outlook.

Glaukos CFO’s fresh 20,000‑share buy signals bullish confidence amid new regulatory wins for NCX 470 in China and Japan, hinting at near‑term upside.

Glaukos CFO’s balanced buy‑sell trade shows confidence in the company’s rising valuation and hedges short‑term volatility while backing its glaucoma therapy future.

GLAUKOS CFO’s mixed buy‑sell trade shows bullish confidence in the glaucoma therapy stock, hinting at future upside despite its negative P/E.

Explore the implications of Navratil Tomas’s recent Glaukos insider sale—understand the impact on liquidity, investor sentiment, and the company’s growth outlook.

Glaukos insider buys signal board confidence amid price dip and a $6 B cap‑growth focus on micro‑injectable glaucoma tech—investors see a potential rebound.

Insider buying at Glaukos Corp signals CEO confidence in new glaucoma therapies – learn how the 2026 Form 4 filings could boost future upside.

Insider sales at Glaukos Corp show routine portfolio rebalancing; executives keep significant stakes while stock remains volatile with a steep negative P/E.